Grass pollen allergy immunotherapy low dose - ALK-Abello

Drug Profile

Grass pollen allergy immunotherapy low dose - ALK-Abello

Alternative Names: Avanz; Grass pollen allergy vaccine - ALK-Abello

Latest Information Update: 01 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis

Most Recent Events

  • 01 Oct 2015 ALK-Abelló completes a phase II trial in Allergic rhinoconjunctivitis in Germany (NCT02166268)
  • 24 Apr 2012 ALK-Abelló completes a phase II/III trial in Allergic rhinoconjunctivitis in Spain (NCT01454531)
  • 10 Feb 2012 ALK-Abelló completes enrolment in its phase II/III trial for Allergic rhinoconjunctivitis in Austria, Germany and Spain (NCT01438827)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top